Therapeutic strategies targeted at the PI3K/Akt signaling pathway such as using adenovirus-carrying phosphatase and tensin homologue deleted on chromosome ten (PTEN) cDNA [40], dominant-negative class IA PI3K-TAT fusion protein [41], and PI3K non-selective and isoform-selective small molecule inhibitors [42], [43], [44] have demonstrated beneficial effects in experimental asthma models. This evidence concerns the gene AKT1 and asthma.